ATE362977T1 - Nicht pathogene stämme des hiv-1 - Google Patents

Nicht pathogene stämme des hiv-1

Info

Publication number
ATE362977T1
ATE362977T1 AT95908826T AT95908826T ATE362977T1 AT E362977 T1 ATE362977 T1 AT E362977T1 AT 95908826 T AT95908826 T AT 95908826T AT 95908826 T AT95908826 T AT 95908826T AT E362977 T1 ATE362977 T1 AT E362977T1
Authority
AT
Austria
Prior art keywords
hiv
region
nef
ltr
blood
Prior art date
Application number
AT95908826T
Other languages
English (en)
Inventor
Nicholas Deacon
Jennifer Learmont
Dale Mcphee
Suzanne Crowe
David Cooper
Original Assignee
Macfarlane Burnet Ct For Medic
Australian Red Cross Soc Nsw D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM3864A external-priority patent/AUPM386494A0/en
Priority claimed from AUPM4002A external-priority patent/AUPM400294A0/en
Priority claimed from AUPN0284A external-priority patent/AUPN028494A0/en
Application filed by Macfarlane Burnet Ct For Medic, Australian Red Cross Soc Nsw D filed Critical Macfarlane Burnet Ct For Medic
Application granted granted Critical
Publication of ATE362977T1 publication Critical patent/ATE362977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT95908826T 1994-02-14 1995-02-14 Nicht pathogene stämme des hiv-1 ATE362977T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM3864A AUPM386494A0 (en) 1994-02-14 1994-02-14 Non-pathogenic strains of hiv-1
AUPM4002A AUPM400294A0 (en) 1994-02-21 1994-02-21 II. Non-pathogenic strains of hiv-1
AUPN0284A AUPN028494A0 (en) 1994-12-23 1994-12-23 III. Non-pathogenic strains of HIV-1

Publications (1)

Publication Number Publication Date
ATE362977T1 true ATE362977T1 (de) 2007-06-15

Family

ID=34068526

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908826T ATE362977T1 (de) 1994-02-14 1995-02-14 Nicht pathogene stämme des hiv-1

Country Status (9)

Country Link
US (1) US6010895A (de)
EP (1) EP0754223B8 (de)
JP (1) JPH10500281A (de)
AT (1) ATE362977T1 (de)
CA (1) CA2183154A1 (de)
DE (1) DE69535500D1 (de)
IL (1) IL112636A0 (de)
SA (1) SA95160467A (de)
WO (1) WO1995021912A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN302195A0 (en) * 1995-05-17 1995-06-08 Macfarlane Burnet Centre For Medical Research Limited, The Non-pathogenic strains of hiv-1 and methods for detecting same
ES2313723T3 (es) * 1994-12-27 2009-03-01 Immunoscience, Inc. Vacunas del virus de la inmunodeficiencia humana y agentes terapeuticos que contienen mutantes de delecion de nef de hiv-1 deteriorados en replicacion.
AU7276198A (en) * 1997-05-02 1998-11-27 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease
DE19850186A1 (de) * 1998-10-30 2000-05-25 Roche Diagnostics Gmbh Neue Primer und Sonden zum Nachweis von HIV
US6472155B1 (en) * 1999-06-08 2002-10-29 The Regents Of The University Of California Species specific identification of spore-producing microbes using the gene sequence of small acid-soluble spore coat proteins for amplification based diagnostics
DE19936003A1 (de) * 1999-08-03 2001-02-15 Dade Behring Marburg Gmbh Lentivirus aus der Gruppe der Immunschwächeviren der Drillaffen(mandrillus leucophaeus) und ihre Verwendung
US8323928B2 (en) * 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US6605427B2 (en) 2000-02-10 2003-08-12 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US6503756B1 (en) * 2000-09-22 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of syntaxin 4 interacting protein expression
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
EP1989326A4 (de) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex-verfolgungstest
EP2347011B1 (de) * 2008-10-27 2017-01-18 QIAGEN Gaithersburg, Inc. Rna/dna hybrid detektionsverfahren
AU2010208311B2 (en) * 2009-01-28 2016-07-07 Qiagen Gaithersburg, Inc. Sequence-specific large volume sample preparation method and assay
JP5738278B2 (ja) * 2009-05-01 2015-06-24 キアジェン ゲイサーズバーグ インコーポレイテッド 試料中のｒｎａスプライシング形態を検出するための非標的増幅法
ES2615728T3 (es) * 2010-01-29 2017-06-08 Qiagen Gaithersburg, Inc. Métodos y composiciones para una purificación y un análisis múltiple específico de secuencia de ácidos nucleicos
CN102822353A (zh) 2010-01-29 2012-12-12 奇亚根盖瑟斯堡股份有限公司 确定和确认样品中存在hpv的方法
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9422593B2 (en) 2010-05-19 2016-08-23 Qiagen Gaithresburg, Inc Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
AU2012220575B2 (en) 2011-02-24 2017-01-12 Qiagen Gaithersburg, Inc. Materials and methods for detection of HPV nucleic acid
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242216A1 (de) * 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Nicht cytopathischer Klon von menschlichem T-Zellen lymphotropen Virus Typ-III
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
WO1990013641A1 (en) * 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
EP0537247A4 (en) * 1990-06-19 1993-09-08 Immuvax Nonpathogenic variant virus
WO1991019817A1 (en) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute EXPRESSION VECTORS CONTAINING THE HIV nef GENE TO ENHANCE REPLICATION EFFICIENCY
EP0491930B1 (de) * 1990-07-12 1997-01-15 The President And Fellows Of Harvard College Primaten-lentivirus impfstoffe
EP0478842A1 (de) * 1990-10-05 1992-04-08 PALL BIOMEDIZIN GmbH Filter zur Filtration menschlicher Cerebronspinalflüssigkeit
JPH0578386A (ja) * 1991-08-20 1993-03-30 Sanyo Kokusaku Pulp Co Ltd 新規な抗ｈｉｖ剤及びその製造方法
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
AU5848794A (en) * 1993-02-05 1994-08-29 Regents Of The University Of California, The Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
US5962635A (en) * 1993-05-18 1999-10-05 Biomolecular Research Institute Ltd. Therapeutic compounds
GB9311043D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Inhibitors of nef-cd4 binding
WO1994029437A1 (en) * 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
FR2720068A1 (fr) * 1994-05-20 1995-11-24 Inst Nat Sante Rech Med Protéines d'interaction avec la protéine Nef du virus HIV1, séquences d'acides nucléiques codant pour ces protéines et leur utilisation pour le criblage d'agents anti-viraux anti-HIV.
ES2313723T3 (es) * 1994-12-27 2009-03-01 Immunoscience, Inc. Vacunas del virus de la inmunodeficiencia humana y agentes terapeuticos que contienen mutantes de delecion de nef de hiv-1 deteriorados en replicacion.
US7506947B2 (en) * 2004-03-09 2009-03-24 Canon Kabushiki Kaisha Ink jet printing apparatus and method using media shape detection

Also Published As

Publication number Publication date
EP0754223A1 (de) 1997-01-22
IL112636A0 (en) 1995-05-26
CA2183154A1 (en) 1995-08-17
EP0754223B8 (de) 2007-08-01
EP0754223A4 (de) 1997-09-17
US6010895A (en) 2000-01-04
SA95160467A (ar) 2005-12-03
DE69535500D1 (de) 2007-07-05
EP0754223B1 (de) 2007-05-23
WO1995021912A1 (en) 1995-08-17
JPH10500281A (ja) 1998-01-13

Similar Documents

Publication Publication Date Title
ATE362977T1 (de) Nicht pathogene stämme des hiv-1
Gessain et al. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations
Gao et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin
Simon et al. Cellular and plasma viral load in patients infected with HIV-2
Sova et al. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1
Weniger et al. The molecular epidemiology of HIV in Asia
McCutchan et al. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria
US7078516B1 (en) Nucleotide sequences derived from the genome of retroviruses of the hiv-1, hiv-2 and siv type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
Groenink et al. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain
Burger et al. Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts.
Vicente et al. The HIV epidemic in the Amazon Basin is driven by prototypic and recombinant HIV-1 subtypes B and F
Quiñones-Mateu et al. Recombination in HIV-1: update and implications
Papadopulos-Eleopulos et al. HIV & AIDS-The Isolation of HIV; Has it really been achieved? The case against
Yanagihara Geographic-specific genotypes or topotypes of human T-cell lymphotropic virus type I as markers for early and recent migrations of human populations
US6037165A (en) Methods for the preparation of human immunodeficiency virus type 2 (HIV-2) and antigens encoped thereby
Ellenberger et al. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development
McDonald et al. Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function
Beddows et al. Performance of two commercially available sequence‐based HIV‐1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes
Yu et al. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand
Malamud et al. HIV in the oral cavity: virus, viral inhibitory activity, and antiviral antibodies: a review
Sova et al. Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo
Poiesz et al. Prevalence of HTLV‐I‐associated T‐cell lymphoma
Coul et al. Genetic evidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children
Escaich et al. Comparison of HIV detection by virus isolation in lymphocyte cultures and molecular amplification of HIV DNA and RNA by PCR in offspring of seropositive mothers
CONNOR et al. Biological cloning of functionally diverse quasispecies of HIV-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties